Artificial intelligence is not yet able to fully replace human experts in important drug safety work, FDA cautions.
AI and Adverse Events: Tech Not Ready For Prime Time For Case Safety Reports, US FDA Says
FDA leadership weighs in on limitations of AI as part of rollout of new technology meeting program that looks to give industry and other stakeholders a chance to inform future regulation.
